1. Genomic analysis of local variation and recent evolution in Plasmodium vivax.

    Nature Genetics 48(8):959 (2016) PMID 27348299 PMCID PMC4966634

    The widespread distribution and relapsing nature of Plasmodium vivax infection present major challenges for the elimination of malaria. To characterize the genetic diversity of this parasite in individual infections and across the population, we performed deep genome sequencing of >200 clinical ...
  2. Can new treatment developments combat resistance in malaria?

    Expert Opinion on Pharmacotherapy 17(10):1303 (2016) PMID 27191998

  3. Limited Polymorphism of the Kelch Propeller Domain in Plasmodium malariae and P. ovale Isolates from Thailand.

    Antimicrobial Agents and Chemotherapy 60(7):4055 (2016) PMID 27114275 PMCID PMC4914644

    Artemisinin resistance in Plasmodium falciparum, the agent of severe malaria, is currently a major obstacle to malaria control in Southeast Asia. A gene named "kelch13" has been associated with artemisinin resistance in P. falciparum The orthologue of the kelch gene in P. vivax was identified an...
  4. Antimalarial mass drug administration: ethical considerations.

    International Health 8(4):235 (2016) PMID 27481834 PMCID PMC4967848

    Falciparum malaria is a major cause of death and illness in tropical countries, particularly in childhood. In endemic countries, a significant proportion of the community is infected with malaria asymptomatically. One promising way to eliminate malaria is to give the entire population malaria tr...
  5. Population pharmacokinetics of oseltamivir and oseltamivir carboxylate in obese and non-obese volunteers.

    British Journal of Clinical Pharmacology 81(6):1103 (2016) PMID 26810861 PMCID PMC4876175

    The aims of the present study were to compare the pharmacokinetics of oseltamivir and its active antiviral metabolite oseltamivir carboxylate in obese and non-obese individuals and to determine the effect of obesity on the pharmacokinetic properties of oseltamivir and oseltamivir carboxylate. Th...
  6. Numerical Distributions of Parasite Densities During Asymptomatic Malaria.

    Journal of Infectious Diseases 213(8):1322 (2016) PMID 26681777 PMCID PMC4799672

    Asymptomatic parasitemia is common even in areas of low seasonal malaria transmission, but the true proportion of the population infected has not been estimated previously because of the limited sensitivity of available detection methods. Cross-sectional malaria surveys were conducted in areas o...
  7. A Randomized Comparison of Chloroquine Versus Dihydroartemisinin-Piperaquine for the Treatment of Plasmodium vivax Infection in Vietnam.

    The Journal of tropical medicine and hygiene 94(4):879 (2016) PMID 26856909 PMCID PMC4824232

    A total of 128 Vietnamese patients with symptomatic Plasmodium vivax mono-infections were enrolled in a prospective, open-label, randomized trial to receive either chloroquine or dihydroartemisinin-piperaquine (DHA-PPQ). The proportions of patients with adequate clinical and parasitological resp...
  8. Sequestration and Red Cell Deformability as Determinants of Hyperlactatemia in Falciparum Malaria.

    Journal of Infectious Diseases 213(5):788 (2016) PMID 26494775 PMCID PMC4747623

    Hyperlactatemia is a strong predictor of mortality in severe falciparum malaria. Sequestered parasitized erythrocytes and reduced uninfected red blood cell deformability (RCD) compromise microcirculatory flow, leading to anaerobic glycolysis. In a cohort of patients with falciparum malaria hospi...
  9. The Community As the Patient in Malaria-Endemic Areas: Preempting Drug Resistance with Multiple First-Line Therapies.

    PLOS Medicine 13(3):e1001984 (2016) PMID 27022739 PMCID PMC4811558

    Maciej F. Boni and colleagues propose deploying multiple first-line combination therapies against malaria within a community to delay drug-resistance evolution.
  10. New insights into the Plasmodium vivax transcriptome using RNA-Seq.

    Scientific reports 6:20498 (2016) PMID 26858037 PMCID PMC4746618

    Historically seen as a benign disease, it is now becoming clear that Plasmodium vivax can cause significant morbidity. Effective control strategies targeting P. vivax malaria is hindered by our limited understanding of vivax biology. Here we established the P. vivax transcriptome of the Intraery...
  11. History of malaria treatment as a predictor of subsequent subclinical parasitaemia: a cross-sectional survey and malaria case records from three villages in Pailin, western Cambodia.

    Malaria Journal 15(1):240 (2016) PMID 27118311 PMCID PMC4845326

    Treatment of the sub-clinical reservoir of malaria, which may maintain transmission, could be an important component of elimination strategies. The reliable detection of asymptomatic infections with low levels of parasitaemia requires high-volume quantitative polymerase chain reaction (uPCR), wh...
  12. Clinical trials of artesunate plus sulfadoxine-pyrimethamine for Plasmodium falciparum malaria in Afghanistan: maintained efficacy a decade after introduction.

    Malaria Journal 15(1):121 (2016) PMID 26917051 PMCID PMC4766631

    Combination therapy with artesunate plus sulfadoxine-pyrimethamine (SP) was adopted as recommended treatment for Plasmodium falciparum infection in Afghanistan in 2003. A series of prospective clinical studies examining the efficacy of artesunate plus sulfadoxine-pyrimethamine (AS + SP) against ...
  13. Neutralizing Antibodies against Plasmodium falciparum Associated with Successful Cure after Drug Therapy.

    PLoS ONE 11(7):e0159347 (2016) PMID 27427762 PMCID PMC4948787

    An effective antibody response can assist drug treatment to contribute to better parasite clearance in malaria patients. To examine this, sera were obtained from two groups of adult patients with acute falciparum malaria, prior to drug treatment: patients who (1) have subsequent recrudescent inf...
  14. Comparative genome-wide analysis and evolutionary history of haemoglobin-processing and haem detoxification enzymes in malarial parasites.

    Malaria Journal 15(1):51 (2016) PMID 26821618 PMCID PMC4731938

    Malaria parasites have evolved a series of intricate mechanisms to survive and propagate within host red blood cells. Intra-erythrocytic parasitism requires these organisms to digest haemoglobin and detoxify iron-bound haem. These tasks are executed by haemoglobin-specific proteases and haem bio...
  15. Parasite clearance rates in Upper Myanmar indicate a distinctive artemisinin resistance phenotype: a therapeutic efficacy study.

    Malaria Journal 15(1):185 (2016) PMID 27036739 PMCID PMC4815199

    Artemisinin resistance in Plasmodium falciparum extends across Southeast Asia where it is associated with worsening partner drug resistance and a decline in the efficacy of frontline artemisinin-based combination therapy. Dihydroartemisinin-piperaquine (DP) is an essential component of preventiv...
  16. Asymptomatic Plasmodium infections in 18 villages of southern Savannakhet Province, Lao PDR (Laos).

    Malaria Journal 15(1):296 (2016) PMID 27234446 PMCID PMC4882819

    A large fraction of Plasmodium infections do not cause clinical signs and symptoms of disease and persist at densities in blood that are not detectable by microscopy or rapid diagnostic tests. These infections may be critical as a transmission reservoir in areas of low malaria endemicity. Unders...
  17. Single Low Dose Primaquine (0.25 mg/kg) Does Not Cause Clinically Significant Haemolysis in G6PD Deficient Subjects.

    PLoS ONE 11(3):e0151898 (2016) PMID 27010542 PMCID PMC4807095

    Primaquine is the only drug consistently effective against mature gametocytes of Plasmodium falciparum. The transmission blocking dose of primaquine previously recommended was 0.75 mg/kg (adult dose 45 mg) but its deployment was limited because of concerns over haemolytic effects in patients wit...
  18. Pharmacokinetic properties of intramuscular versus oral syrup paracetamol in Plasmodium falciparum malaria.

    Malaria Journal 15(1):244 (2016) PMID 27118212 PMCID PMC4847232

    Fever is an inherent symptom of malaria in both adults and children. Paracetamol (acetaminophen) is the recommended antipyretic as it is inexpensive, widely available and has a good safety profile, but patients may not be able to take the oral drug reliably. A comparison between the pharmacokine...
  19. Antimalarial activity of artefenomel (OZ439), a novel synthetic antimalarial endoperoxide, in patients with Plasmodium falciparum and Plasmodium vivax malaria: an open-label phase 2 trial.

    The Lancet Infectious Diseases 16(1):61 (2016) PMID 26448141 PMCID PMC4700386

    Artefenomel (OZ439) is a novel synthetic trioxolane with improved pharmacokinetic properties compared with other antimalarial drugs with the artemisinin pharmacophore. Artefenomel has been generally well tolerated in volunteers at doses up to 1600 mg and is being developed as a partner drug in a...
  20. Persistent Plasmodium falciparum and Plasmodium vivax infections in a western Cambodian population: implications for prevention, treatment and elimination strategies.

    Malaria Journal 15(1):181 (2016) PMID 27013512 PMCID PMC4806483

    Subclinical Plasmodium parasitaemia is an important reservoir for the transmission and persistence of malaria, particularly in low transmission areas. Using ultrasensitive quantitative PCR (uPCR) for the detection of parasitaemia, the entire population of three Cambodian villages in Pailin provi...